{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:17:51Z","timestamp":1768321071931,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Applied Radiation and Isotopes"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.apradiso.2020.109219","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:47:44Z","timestamp":1589374064000},"page":"109219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The importance of optimal ROIs delineation for FBPA-PET before BNCT"],"prefix":"10.1016","volume":"163","author":[{"given":"Yi-Wen","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Cheng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Sin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Shuo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.apradiso.2020.109219_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3892\/ol.2011.265","article-title":"Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions","volume":"2","author":"Ariyoshi","year":"2011","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib33","first-page":"35","article-title":"Boron Delivery Agents for Neutron Capture Therapy of Cancer","volume":"38","author":"Barth","year":"2018","journal-title":"Cancer Commun (Lond)"},{"issue":"12","key":"10.1016\/j.apradiso.2020.109219_bib2","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/1097-0142(19921215)70:12<2995::AID-CNCR2820701243>3.0.CO;2-#","article-title":"Boron neutron capture therapy for cancer. Realities and prospects","volume":"70","author":"Barth","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.apradiso.2020.109219_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0360-3016(97)00891-2","article-title":"Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory","volume":"40","author":"Chadha","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib4","article-title":"Boron neutron capture therapy: a new generation of targeted charged-particle radiotherapy","volume":"13","author":"Chen","year":"2019","journal-title":"Biomed. J. Sci. & Tech. Res."},{"issue":"2","key":"10.1016\/j.apradiso.2020.109219_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2307\/3579926","article-title":"Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity","volume":"149","author":"Coderre","year":"1998","journal-title":"Radiat. Res."},{"issue":"1\u20132","key":"10.1016\/j.apradiso.2020.109219_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1005741919442","article-title":"Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results","volume":"33","author":"Coderre","year":"1997","journal-title":"J. Neuro Oncol."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib7","first-page":"138","article-title":"Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma","volume":"50","author":"Coderre","year":"1990","journal-title":"Canc. Res."},{"issue":"23","key":"10.1016\/j.apradiso.2020.109219_bib8","first-page":"6377","article-title":"Selective targeting of boronophenylalanine to melanoma in BALB\/c mice for neutron capture therapy","volume":"47","author":"Coderre","year":"1987","journal-title":"Canc. Res."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3579742","article-title":"The radiation biology of boron neutron capture therapy","volume":"151","author":"Coderre","year":"1999","journal-title":"Radiat. Res."},{"issue":"2","key":"10.1016\/j.apradiso.2020.109219_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Canc."},{"issue":"3","key":"10.1016\/j.apradiso.2020.109219_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2307\/3578693","article-title":"Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin","volume":"138","author":"Fukuda","year":"1994","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.apradiso.2020.109219_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF03178777","article-title":"Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor","volume":"26","author":"Fukuda","year":"2003","journal-title":"Australas. Phys. Eng. Sci. Med."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13550-014-0070-2","article-title":"FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model","volume":"4","author":"Hanaoka","year":"2014","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.apradiso.2020.109219_bib14","first-page":"447","article-title":"Clinical experience of boron neutron capture therapy for malignant brain tumors (1968-1985)","author":"Hatanaka","year":"1986","journal-title":"Neutron Capture Ther."},{"issue":"5","key":"10.1016\/j.apradiso.2020.109219_bib15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0360-3016(94)90479-0","article-title":"Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy","volume":"28","author":"Hatanaka","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.apradiso.2020.109219_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12149-019-01347-8","article-title":"4-Borono-2-(18)F-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research","volume":"33","author":"Ishiwata","year":"2019","journal-title":"Ann. Nucl. Med."},{"issue":"3","key":"10.1016\/j.apradiso.2020.109219_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008390-199209000-00005","article-title":"A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine","volume":"2","author":"Ishiwata","year":"1992","journal-title":"Melanoma Res."},{"issue":"Suppl. 1","key":"10.1016\/j.apradiso.2020.109219_bib18","first-page":"1039","article-title":"Selection criteria for boron neutron capture therapy candidates based on the SUV images of FBPA PET","volume":"58","author":"Isohashi","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13550-016-0230-7","article-title":"Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-(18)F-fluoro-phenylalanine (FBPA) PET study","volume":"6","author":"Isohashi","year":"2016","journal-title":"EJNMMI Res."},{"issue":"11","key":"10.1016\/j.apradiso.2020.109219_bib20","first-page":"1762","article-title":"Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning","volume":"38","author":"Kabalka","year":"1997","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.apradiso.2020.109219_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin. Ultrasound CT MR"},{"issue":"7","key":"10.1016\/j.apradiso.2020.109219_bib22","first-page":"2657","article-title":"Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model","volume":"32","author":"Lin","year":"2012","journal-title":"Anticancer Res."},{"issue":"14","key":"10.1016\/j.apradiso.2020.109219_bib23","first-page":"3308","article-title":"Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent","volume":"53","author":"Matalka","year":"1993","journal-title":"Canc. Res."},{"key":"10.1016\/j.apradiso.2020.109219_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/978-1-4615-3384-9_126","article-title":"Advances in the control of human cutaneous primary and metastatic melanoma by thermal neutron capture therapy","author":"Mishima","year":"1992","journal-title":"Prog. Neutron Capture Ther. Cancer"},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1227\/01.neu.0000279727.90650.24","article-title":"Boron neutron capture therapy for malignant tumors related to meningiomas","volume":"61","author":"Miyatake","year":"2007","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.apradiso.2020.109219_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejca.2008.10.028","article-title":"Evaluation of lymph nodes with RECIST 1.1","volume":"45","author":"Schwartz","year":"2009","journal-title":"Eur. J. Canc."},{"issue":"6","key":"10.1016\/j.apradiso.2020.109219_bib27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2967\/jnumed.106.035774","article-title":"Partial-volume effect in PET tumor imaging","volume":"48","author":"Soret","year":"2007","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.apradiso.2020.109219_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nucmedbio.2005.01.005","article-title":"Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model","volume":"32","author":"Wang","year":"2005","journal-title":"Nucl. Med. Biol."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijrobp.2016.02.028","article-title":"Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: a prospective phase I\/II trial","volume":"95","author":"Wang","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.apradiso.2020.109219_bib30","first-page":"37","article-title":"Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor","volume":"38","author":"Wang","year":"2018","journal-title":"Canc. Commun."},{"issue":"6","key":"10.1016\/j.apradiso.2020.109219_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12149-017-1172-5","article-title":"Practical calculation method to estimate the absolute boron concentration in tissues using (18)F-FBPA PET","volume":"31","author":"Watabe","year":"2017","journal-title":"Ann. Nucl. Med."},{"issue":"7","key":"10.1016\/j.apradiso.2020.109219_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1118\/1.598618","article-title":"Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics","volume":"26","author":"Wheeler","year":"1999","journal-title":"Med. Phys."}],"container-title":["Applied Radiation and Isotopes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804320303481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804320303481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:13:53Z","timestamp":1760847233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969804320303481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":33,"alternative-id":["S0969804320303481"],"URL":"https:\/\/doi.org\/10.1016\/j.apradiso.2020.109219","relation":{},"ISSN":["0969-8043"],"issn-type":[{"value":"0969-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of optimal ROIs delineation for FBPA-PET before BNCT","name":"articletitle","label":"Article Title"},{"value":"Applied Radiation and Isotopes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apradiso.2020.109219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109219"}}